AYAs With Hematologic Malignancies Have Higher Risk of Early Death
The risk of early death in AYAs with cancer depends on the type of malignancy they have as well as multiple demographic factors, a study suggests.
The risk of early death in AYAs with cancer depends on the type of malignancy they have as well as multiple demographic factors, a study suggests.
A distinct mutational landscape and worse outcomes were seen for patients with MDS/AML vs those with MDS.
The approval was based on data from the phase 3 SEQUOIA and ALPINE studies in patients with CLL/SLL.
Posoleucel appears safe and effective for treating refractory viral infections occurring after allogeneic hematopoietic stem cell transplant.
Lumoxiti was approved by the FDA in September 2018 for the treatment of adults with relapsed or refractory hairy cell leukemia.
Researchers sought to determine whether race, ethnicity, or BMI would have an impact on CAR T-cell therapy outcomes in patients with B-ALL.
Olverembatinib has demonstrated antitumor activity in patients with chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia.
Undergoing HSCT within 4 weeks of SARS-CoV-2 infection is associated with an increased risk of death at 90 days after HSCT, real-world data suggest.
AML research presented at ASH 2022 highlighted promising combination regimens and suggested that some patients may benefit from less intensive treatment.
Prior to the introduction of CAR T-cell therapy, pediatric patients with ALL had limited treatment options for relapsed or refractory disease.